0001126234-21-000112.txt : 20210813 0001126234-21-000112.hdr.sgml : 20210813 20210813163154 ACCESSION NUMBER: 0001126234-21-000112 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210811 FILED AS OF DATE: 20210813 DATE AS OF CHANGE: 20210813 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McCracken Joseph S CENTRAL INDEX KEY: 0001632454 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35342 FILM NUMBER: 211172686 MAIL ADDRESS: STREET 1: C/O NEXVET BIOPHARMA PLC STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK STATE: L2 ZIP: 00000 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LUMOS PHARMA, INC. CENTRAL INDEX KEY: 0001126234 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 421491350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4200 MARATHON BLVD. STREET 2: SUITE 200 CITY: AUSTIN STATE: TX ZIP: 78756 BUSINESS PHONE: 512-215-2630 MAIL ADDRESS: STREET 1: 4200 MARATHON BLVD. STREET 2: SUITE 200 CITY: AUSTIN STATE: TX ZIP: 78756 FORMER COMPANY: FORMER CONFORMED NAME: NEWLINK GENETICS CORP DATE OF NAME CHANGE: 20001012 4 1 wf-form4_162888669898993.xml FORM 4 X0306 4 2021-08-11 0 0001126234 LUMOS PHARMA, INC. (LUMO) 0001632454 McCracken Joseph S 4200 MARATHON BLVD SUITE 200 AUSTIN TX 78756 1 0 0 0 Common Stock 2021-08-11 4 P 0 7475 7.546 A 8551 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.475 to $7.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in this footnote to this Form 4. Includes 473 restricted stock units ("RSUs") previously reported as holdings of the Reporting Person granted under the Issuer's 2010 Non-Employee Directors' Stock Award Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in a series of two successive annual installments with the next installment occurring on April 3, 2022, in each case subject to the Reporting Person's continuous service as of such date. /s/ Ryan Trytten, attorney-in-fact 2021-08-13